Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
The Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center has welcomed five new clinician-scientists specializing in leukemia.
"Cancer biology is in the midst of a major transition that has led from a primary focus on oncogenes to a focus on systems," say the Columbia editorial authors, Dr. Victor Grann and Maxine Ashby-Thompson.